Dr Kola Tytler MBBS CertHE MBA MSt MRCGPClinical Lead • iatroX
Counselling after Abrysvo at 19 weeks: Explain that this is earlier than the 24–36-week gestational window evaluated in the supplied maternal trial, so that trial cannot quantify safety or infant protection specifically after a dose at 19 weeks SmPC Abrysvo. This evidence gap does not establish that harm has occurred, but it also does not support a guarantee of safety or adequate infant protection at this timing SmPC Abrysvo.
- Explain the intended benefit: maternal vaccination produces RSV antibodies that cross the placenta to protect the infant against RSV-associated lower respiratory tract disease; the supporting efficacy evidence comes from vaccination at 24–36 weeks SmPC Abrysvo.
- Allow discussion of concerns: provide balanced information about the intended benefit and the uncertainty associated with early administration, rather than offering unsupported reassurance; general vaccination counselling guidance supports discussing concerns about safety, efficacy and need SmPC Abrysvo,NICE CKS.
- Further vaccination: the supplied excerpts do not specify whether a dose given at 19 weeks should be repeated, so they do not support automatically scheduling another dose; Abrysvo use should follow official recommendations SmPC Abrysvo.
- Follow-up and monitoring: these excerpts contain no specific early-administration protocol, observation period, additional fetal surveillance schedule or adverse-event counselling details, so a specific monitoring plan cannot be derived from them SmPC Abrysvo,NICE CKS.
- Routine antenatal care: maintain the usual antenatal appointments and screening programme, while recognising that the supplied antenatal guidance does not address additional follow-up after an early Abrysvo dose NICE CKS.
Key limitation: the supplied sources do not resolve the administration-error pathway or repeat-dose decision; these require the applicable official vaccination recommendations rather than extrapolation from the trial SmPC Abrysvo.